As described in more detail in other contributions in this issue of Seminars in Nuclear
Medicine, prostate-specific membrane antigen (PSMA) has become one of the most …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA),
making this antigen a suitable target for radioligand therapy of the disease. Here we report …

Prostate specific membrane antigen (PSMA) has become a major focus point in the research
and development of prostate cancer (PCa) imaging and therapeutic strategies using …

In the last two decades, various nanomaterials have attracted increasing attention in medical
science owing to their unique physical and chemical characteristics. Incorporating …

Simple Summary One of the most frequently diagnosed cancer in men is adenocarcinoma of
the prostate. Once the disease is metastatic, only very limited treatment options are …

Ovarian cancer is the leading cause of death from gynecologic cancer in the developed
countries. It is usually diagnosed in advanced stage since it is often symptomless or …

This review deals with the development of peptide-based radiopharmaceuticals for the use
with positron emission tomography and peptide receptor radiotherapy. It discusses the pros …

Prostate‐specific membrane antigen (PSMA) is the most promising target for radioligand
therapy of prostate cancer. The aim of this study was to prepare a small molecular ligand p …

Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes.
Many subtypes of lymphoma, such as Burkitt′ s lymphoma and diffuse large B cell …